First drug-candidate compounds discovered using AI licensed for development

Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.

About the author

David Brown

View all posts

Leave a Reply

Your email address will not be published.